Focus Partners Wealth
ARQT icon

Focus Partners Wealth’s Arcutis Biotherapeutics ARQT Stock Holding History

Focus Partners Wealth’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.54M Sell
65,449
-1,124
-2% -$28.7K ﹤0.01% 1428
2025
Q4 		$1.93M Buy
66,573
+1,377
+2% +$35.3K ﹤0.01% 1334
2025
Q3 		$1.24M Buy
65,196
+490
+0.8% +$7.73K ﹤0.01% 1201
2025
Q2 		$907K Buy
64,706
+756
+1% +$10.6K ﹤0.01% 1185
2025
Q1 		$1M Sell
63,950
-233
-0.4% -$3.28K ﹤0.01% 1071
2024
Q4 		$894K Buy
+64,183
New +$703K ﹤0.01% 1090
2024
Q3 		– Sell
-63,100
Closed -$680K – 1578
2024
Q2 		$680K Hold
63,100
– – ﹤0.01% 878
2024
Q1 		$558K Buy
+63,100
New +$471K ﹤0.01% 706

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return